Biodesix presents data on VeriStrat biomarker study at ASCO 2013
Biodesix closed on $8.8 million in a follow-on sale of its Series D preferred shares.
Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.
Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.
Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.
Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.
Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.
The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.